Roche’s Genentech opens up the world with new ad for Vabysmo
May 1, 2023
Source: drugdu
139
Adults facing wet age-related macular degeneration (AMD) and diabetic macular edema (DME) fear their world getting smaller due to loss of eyesight. Roche’s Genentech addresses that issue head-on in its first DTC ad for Vabysmo.
The new “Open up your world with Vabysmo” campaign was developed with input from patients, caregivers, advocacy groups and the retinal community impacted by wet AMD and DME.
“One of the critical insights was that many of these patients felt when they were losing their vision it made their world feel really small—they didn't get to go out as much, they weren't necessarily doing their daily activities of living because they felt like they were losing their sight and therefore inhibiting that ability,” Jennifer Kim, Genentech’s vice president and head of ophthalmology, said.
“So that's how we developed that concept around open up your world. The idea of the campaign is to show how getting treatments with Vabysmo can actually help to open up their world again by improving their vision.
Reference:https://endpts.com/genentech-debuts-first-diabetes-and-age-related-eye-disease-drug-campaign/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions November 22, 2024
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
